Mezcla

Ultra-fast insulin aspart “Fiasp” has disappeared from Russian pharmacies

In the first quarter, government purchases of insulin aspart Fiasp, after injection of which you can almost immediately eat, decreased by 95 percent. It can no longer be found in pharmacies, writes Kommersant newspaper.

According to Headway Company estimates, government purchases of insulin aspart in January–March 2024 decreased year-on-year by 70 percent. Among short-acting drugs, Fiasp from the Danish Novo Nordisk was previously the leader in terms of volume – its purchases decreased by 95 percent. According to AptekaMos, this drug has also disappeared from pharmacies in a number of cities, including Moscow, the Moscow region and St. Petersburg.

Novo Nordisk explains the delays in deliveries due to increased demand. According to RNC Pharma, in January-February 2024, half as much Fiasp was supplied to Russia as a year earlier – 90 thousand versus 200 thousand packages. Responding to a request from one of the public organizations, the drug manufacturer said that the next delivery of Fiasp is expected only in June of this year.

President of the Moscow Diabetes Association Elvira Gustova told Kommersant that problems with the purchase of the drug began at the end of 2023, and in 2024 some regions were no longer able to purchase Fiasp.

There is an analogue of Fiasp on the market from the Russian Geropharm, but its supply volume is still small. According to Headway Company, at the beginning of the year the company produced 300 thousand packages.

Fiasp is an ultra-fast insulin that allows diabetic patients to eat almost immediately after injection. In Russia, patients with diabetes can receive insulin for free, but some prefer to buy specific drugs themselves from pharmacies.

  • For more: DC & People website and for social networking, you can follow us on Facebook
  • Source of information and images “independent”

Related Articles

Back to top button

Discover more from DC & People

Subscribe now to keep reading and get access to the full archive.

Continue reading